Why is Parmax Pharma falling/rising?

As of 26-Aug, Parmax Pharma Ltd is currently priced at 36.40, reflecting an increase of 0.9 or 2.54%. Despite this positive movement today, the stock has underperformed in the short term, with a 1-week decline of 3.83% and a 1-month decline of 3.63%. The stock is trading below its moving averages across various time frames, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 82.42% compared to the 5-day average. While the stock has managed to generate a 7.06% return over the past year, it faces challenges such as a negative book value and weak long-term growth, with net sales declining by 43.96% in the latest six months.
In the broader market context, the Sensex has shown a slight decline of 1.05% over the past week and 0.83% over the past month, suggesting that the overall market sentiment is also bearish. However, Parmax Pharma's performance today has outpaced the sector by 4.34%, indicating some short-term resilience. Despite this, the company's weak fundamentals, including a poor EBIT to interest ratio and negative EBITDA, contribute to a perception of risk among investors. This combination of factors suggests that while there may be short-term gains, the long-term outlook remains concerning, which could lead to further volatility in the stock price.